Vera Therapeutics (VERA) Competitors $23.77 -0.76 (-3.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$23.54 -0.23 (-0.97%) As of 09/12/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. NUVL, TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, and ADMAShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Nuvalent TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Vera Therapeutics (NASDAQ:VERA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Do insiders & institutionals have more ownership in VERA or NUVL? 99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 16.3% of Vera Therapeutics shares are held by company insiders. Comparatively, 10.2% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, VERA or NUVL? Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$152.15M-$3.58-6.64NuvalentN/AN/A-$260.76M-$4.90-16.42 Which has more risk and volatility, VERA or NUVL? Vera Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Is VERA or NUVL more profitable? Nuvalent's return on equity of -32.58% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -46.70% -39.46% Nuvalent N/A -32.58%-30.14% Does the media refer more to VERA or NUVL? In the previous week, Nuvalent had 5 more articles in the media than Vera Therapeutics. MarketBeat recorded 14 mentions for Nuvalent and 9 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.44 beat Nuvalent's score of 0.87 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer VERA or NUVL? Vera Therapeutics currently has a consensus price target of $63.00, suggesting a potential upside of 165.04%. Nuvalent has a consensus price target of $120.91, suggesting a potential upside of 50.25%. Given Vera Therapeutics' higher possible upside, research analysts clearly believe Vera Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Nuvalent 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 SummaryVera Therapeutics beats Nuvalent on 7 of the 13 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.52B$3.20B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-6.6421.4375.3425.98Price / SalesN/A430.69514.97181.19Price / CashN/A46.6837.5660.44Price / Book2.629.6112.156.29Net Income-$152.15M-$53.29M$3.29B$271.07M7 Day Performance-1.74%0.13%0.75%3.87%1 Month Performance8.19%5.61%4.82%4.88%1 Year Performance-36.63%10.49%60.59%26.12% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics2.8876 of 5 stars$23.77-3.1%$63.00+165.0%-33.3%$1.52BN/A-6.6440Positive NewsNUVLNuvalent2.9909 of 5 stars$79.83-1.3%$120.91+51.5%-1.5%$5.83BN/A0.0040Insider TradeTGTXTG Therapeutics4.216 of 5 stars$32.38+0.5%$46.25+42.8%+38.7%$5.11B$329M87.51290Positive NewsInsider TradeMRUSMerus2.9063 of 5 stars$67.19-0.4%$88.75+32.1%+41.6%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.4283 of 5 stars$54.10-1.4%$71.60+32.3%+22.6%$4.99B$37.31M0.00460News CoveragePTCTPTC Therapeutics3.668 of 5 stars$56.95-0.5%$69.00+21.2%+86.8%$4.55B$806.78M8.171,410News CoveragePositive NewsInsider TradeKRYSKrystal Biotech4.9304 of 5 stars$145.20-3.4%$210.38+44.9%-26.6%$4.35B$290.52M30.54210Positive NewsPCVXVaxcyte2.2487 of 5 stars$32.41-1.8%$130.00+301.1%-71.8%$4.29BN/A0.00160News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.3781 of 5 stars$25.39+0.5%$28.88+13.7%+48.0%$4.26B$957.80M19.09510News CoverageAnalyst ForecastACLXArcellx2.2364 of 5 stars$71.11-2.1%$114.31+60.7%+1.9%$4.03B$107.94M0.0080Positive NewsADMAADMA Biologics3.7087 of 5 stars$16.42-2.7%$27.67+68.5%-8.7%$4.03B$426.45M19.09530Positive News Related Companies and Tools Related Companies Nuvalent Competitors TG Therapeutics Competitors Merus Competitors CRISPR Therapeutics Competitors PTC Therapeutics Competitors Krystal Biotech Competitors Vaxcyte Competitors ACADIA Pharmaceuticals Competitors Arcellx Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
